Register for our free email digests:
Generics
Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Aspen Will Pay UK's NHS £8m In Landmark Deal Following Competition Probe
Aspen has agreed to pay the National Health Service £8m following an investigation by the Competition and Markets Authority.
Dr Reddy's Is Knocked Back On US NuvaRing And Copaxone Rivals
Dr Reddy’s has received a further CRL from the US Food and Drug Administration over its application for a generic rival to Merck Sharp & Dohme’s NuvaRing contraceptive, along with a CRL for its version of Teva’s Copaxone.
Pfenex And Alvogen May Face Delay In Teriparatide Equivalence Rating
Pfenex remains hopeful of receiving US approval for its teriparatide hybrid rival to Eli Lilly’s Forteo in October this year. But commercial partner Alvogen may have to wait for a therapeutic equivalence rating to the osteoporosis original.
End Of Road For ‘Too Complex’ EU Pilot Program On Splitting Marketing Licenses
EU regulators have pulled the plug on a pilot program on splitting mutual recognition and decentralized procedure licences. Instead of promoting harmonization of marketing authorizations across the EU and helping companies with their marketing strategies, it has led to more problems.
Pooled Data Among AAM’s Concerns On FDA’s Therapeutic Protein Biosimilars Guidance
Three key areas for improvement in in the FDA’s draft guidance on therapeutic protein biosimilars have been highlighted by industry association AAM. Pharmaceutical giants such as Pfizer, Novartis and Celltrion have also expressed concerns highlight shortcomings and sought clarification.
International Regulators Dismiss Scares On Biosimilar Safety
Biosimilars have been shown to be safe and effective, and healthcare professionals should discount any scaremongering by big pharma to the contrary, the world’s leading regulatory agencies have stated.
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Article
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.